Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

Covid19 Clinical Trial

— CoviDx™  

Official title:

Clinical Evaluation of a SARS-CoV-2 CoviDx™COVID-19 Antigen Self-Test

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05403346
• Other study ID #: CLP-0010
• Status: Terminated
• Start date: May 17, 2022
• Est. completion date: October 31, 2022

Study information

• Verified date: June 2022
• Source: Lumos Diagnostics
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prospective study that will evaluate the clinical agreement of the CoviDx™ Self test compared to SARS-CoV-2 RT-PCR.

Description:

Subjects who are currently experiencing symptoms associated with COVID-19 will be enrolled. Each enrolled subject will either self-collect one sample from the anterior nares or have the sample collected by another lay individual. Each subject will then have a mid-turbinate nasal swab sample collected for comparator test

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 45
• Est. completion date: October 31, 2022
• Est. primary completion date: August 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Mid-turbinate nasal swab collected for SARS-CoV-2 RT-PCR at the same time of CoviDx Rapid Antigen swab collection

• Symptomatic subjects suspected of having COVID-19, first onset of COVID-19-like symptoms (e.g., chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) should not have started more than 5 days from the time of the study visit. Symptoms must be present on the day of CoviDx testing.

• = 2 years of age

• Participants between 2-13 years of age, inclusive, must participate with a guardian who will be collecting the swab.

• Signed Informed Consent

Exclusion Criteria:

• Participants with prior medical or laboratory training

• Unable or unwilling to provide signed, Informed Consent

• Less than 2 years of age

• Received a positive diagnostic test result for COVID-19 in the past 14 days

• Received a negative diagnostic test result for COVID-19 in the last 18 hours

• Study Comparator collection that occurred > 3 hours from CoviDx swab collection

• For symptomatic participants: first onset of COVID-19-like symptoms occurring more than 5 days from study visit

• Invalid or missing study comparator test results

• Use of a non-high-sensitive SARS-CoV-2 test as the comparator SARS-CoV-2 RT-PCR test (e.g., rapid molecular, rapid antigen tests, tests that do not have FDA EUA, a test that was not approved by Sponsor for use in the study)

• Enrollment in another study involving the collection of a nasopharyngeal, mid-turbinate nasal swab or anterior nasal swab within 6 hours of CoviDx testing.

• Indicates they would not use a COVID-19 diagnostic test kit in real life

• Taking any of the following medications or treatments within 7 days of study visit (antivirals (e.g., Remdesivir, Paxlovid) and/or monoclonal antibodies (e.g., REGEN-COV (casirivimab, imdevimab), Sotrovimab (Xevudy), Evusheld)

• Nasal spray administration in the last 48 hours

Related Conditions & MeSH terms

• COVID-19
• Covid19
• SARS-CoV-2

Intervention

Device:
• CoviDx™ Covid-19 Antigen Self-Test
All patients will self-collect a mid-turbinate nasal swab for CoviDx™ Covid-19 Antigen self-testing

Locations

Country	Name	City	State
United States	PAS Research	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Lumos Diagnostics	Rapid Pathogen Screening

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance of CoviDx Covid-19 Antigen Self-Test in nasal swab as compared to a high-sensitive SARSCoV- 2 RT-PCR granted Emergency Use Authorization (EUA) by the FDA	Evaluate the performance (positive percent agreement (PPA) and negative percent agreement (NPA)) of the CoviDx™ COVID-19 Antigen Self-Test for the detection of SARS-CoV-2 virus antigen in anterior nasal swab (NS) samples collected by lay users compared to results obtained from by a high-sensitive SARS-CoV-2 RT-PCR granted Emergency Use Authorization (EUA) by the FDA (comparator test).	60 days